| Trial | Bayer 21343 |
|---|---|
| Cancer Type | Miscellaneous |
| Hospital(s) | Belfast City Hospital |
| Information | An Open-Label, Phase Ib, Dose Escalation And Expansion Study To Evaluate The Safety, Tolerability, Maximum Tolerated Or Administered Dose, Pharmacokinetics, Pharmacodynamics And Efficacy Of The Aryl Hydrocarbon Receptor Inhibitor (AhRi) Bay 2416964 In Combination With Pembrolizumab In Participants With Advanced Solid Tumours |
Bayer 21343
Posted in .